Brief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
30/09/2026 11:22
BRIEF-Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants Sept 30 (Reuters) - Sagimet Biosciences Inc. SGMT.O:
SAGIMET BIOSCIENCES ANNOUNCES PRICING OF $115.0 MILLION UNDERWRITTEN OFFERING OF SERIES A COMMON STOCK AND PRE-FUNDED WARRANTS
SAGIMET BIOSCIENCES - PRICES 8.8 MILLION SERIES A COMMON SHARES AT $10 PER SHARE
Source text: ID:nGNXbKFhFs
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage